Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
2005; Massachusetts Medical Society; Volume: 353; Issue: 16 Linguagem: Inglês
10.1056/nejmoa052122
ISSN1533-4406
AutoresEdward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark,
Tópico(s)Cancer Treatment and Pharmacology
ResumoWe present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
Referência(s)